Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MIRM, NAMS, ERAS, BBIO, ARQT, and represent 55.06% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: MIRM (+$82M), BCRX (+$38M), ERAS (+$32M), PVLA (+$20M), ACRS (+$19M), GLUE (+$17M), CYTK (+$15M), IRON (+$6.1M), MNKD, Xilio Therapeutics.
- Started 4 new stock positions in GLUE, BCRX, Xilio Therapeutics, ACRS.
- Reduced shares in these 10 stocks: Avidity Biosciences Ord (-$71M), ABVX (-$51M), RAPT (-$33M), RVMD (-$12M), TVTX (-$9.2M), BBIO (-$7.2M), DSGN, TRVI, XLO, KRYS.
- Sold out of its positions in ABVX, Avidity Biosciences Ord, DSGN, RAPT, TVTX, XLO.
- Frazier Life Sciences Management was a net buyer of stock by $40M.
- Frazier Life Sciences Management has $3.9B in assets under management (AUM), dropping by 4.39%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 38 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 18.3 | $709M | +13% | 7.7M | 92.38 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 14.0 | $542M | 17M | 32.01 |
|
|
| Erasca (ERAS) | 10.3 | $399M | +8% | 25M | 16.18 |
|
| Bridgebio Pharma (BBIO) | 6.6 | $256M | -2% | 3.4M | 74.26 |
|
| Arcutis Biotherapeutics (ARQT) | 6.0 | $233M | 9.9M | 23.56 |
|
|
| Mbx Biosciences (MBX) | 5.1 | $199M | 6.7M | 29.85 |
|
|
| Phathom Pharmaceuticals (PHAT) | 3.6 | $139M | 13M | 11.11 |
|
|
| Maze Therapeatics (MAZE) | 3.5 | $136M | 4.6M | 29.85 |
|
|
| Krystal Biotech (KRYS) | 3.2 | $124M | 481k | 258.32 |
|
|
| Trevi Therapeutics (TRVI) | 3.1 | $119M | -3% | 9.9M | 11.93 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 2.8 | $110M | +22% | 882k | 124.65 |
|
| Kalvista Pharmaceuticals (KALV) | 2.6 | $100M | 5.0M | 20.13 |
|
|
| Disc Medicine (IRON) | 2.2 | $87M | +7% | 1.4M | 63.94 |
|
| Cytokinetics Com New (CYTK) | 2.0 | $76M | +24% | 1.2M | 65.91 |
|
| Revolution Medicines (RVMD) | 1.7 | $66M | -15% | 676k | 97.25 |
|
| Dyne Therapeutics (DYN) | 1.5 | $57M | 3.2M | 18.13 |
|
|
| Savara (SVRA) | 1.4 | $53M | 9.7M | 5.46 |
|
|
| Tarsus Pharmaceuticals (TARS) | 1.3 | $51M | 729k | 70.15 |
|
|
| Vor Biopharma Com New (VOR) | 1.2 | $45M | 2.5M | 17.84 |
|
|
| Agios Pharmaceuticals (AGIO) | 1.1 | $43M | 1.3M | 33.83 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 1.0 | $38M | NEW | 4.0M | 9.52 |
|
| Zai Lab Adr (ZLAB) | 0.9 | $36M | 1.9M | 18.81 |
|
|
| Aura Biosciences (AURA) | 0.9 | $34M | 5.1M | 6.69 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 0.8 | $32M | +10% | 1.4M | 22.26 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $31M | 133k | 228.73 |
|
|
| Lexeo Therapeutics (LXEO) | 0.7 | $25M | 4.4M | 5.74 |
|
|
| Alkermes SHS (ALKS) | 0.6 | $25M | 701k | 35.36 |
|
|
| Aclaris Therapeutics (ACRS) | 0.5 | $19M | NEW | 4.9M | 3.75 |
|
| Monte Rosa Therapeutics (GLUE) | 0.4 | $17M | NEW | 1.0M | 16.45 |
|
| Immunocore Hldgs Ads (IMCR) | 0.4 | $15M | +25% | 485k | 30.15 |
|
| Mannkind Corp Com New (MNKD) | 0.4 | $15M | +39% | 5.9M | 2.45 |
|
| Valneva Se Sponsored Ads (VALN) | 0.4 | $14M | 2.3M | 6.25 |
|
|
| Evolus (EOLS) | 0.3 | $11M | 2.6M | 4.11 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.3 | $10M | 500k | 20.04 |
|
|
| Allogene Therapeutics (ALLO) | 0.2 | $9.3M | 3.8M | 2.44 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $6.1M | -3% | 4.4M | 1.38 |
|
| Ibio Com New (IBIO) | 0.1 | $3.7M | 2.0M | 1.90 |
|
|
| Xilio Therapeutics | 0.1 | $3.6M | NEW | 423k | 8.41 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2026 Q1 filed May 15, 2026
- Frazier Life Sciences Management 2025 Q4 filed Feb. 13, 2026
- Frazier Life Sciences Management 2025 Q3 filed Nov. 14, 2025
- Frazier Life Sciences Management 2025 Q2 filed Aug. 14, 2025
- Frazier Life Sciences Management 2025 Q1 filed May 15, 2025
- Frazier Life Sciences Management 2024 Q4 filed Feb. 18, 2025
- Frazier Life Sciences Management 2024 Q3 filed Nov. 15, 2024
- Frazier Life Sciences Management 2024 Q2 filed Aug. 15, 2024
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022